Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

Photobiomodulation helps protect hair follicle cells from damage caused by DHT.

This study reports a case where a biologic medication used for atopic dermatitis unexpectedly also treated concurrent alopecia areata.

This study found that PX-12 inhibited the NLRP3 inflammasome and reduced psoriasis-like symptoms in a mouse model, suggesting its potential as a treatment for psoriasis.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

In this study of 40 dermatomyositis patients, most with moderate-severe disease at baseline improved over time in a polyphasic pattern, while those with mild disease often remained stable.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.

This study observed that Polygoni mulitiflori Radix water extracts accelerated hair regrowth in mice by enhancing enzyme activities and increasing IGF-1 gene expression related to hair growth.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

The review found that imiquimod is a promising non-invasive treatment for HPV-related neoplasias, particularly effective for vulvar lesions, but notes that more research is needed to optimize its use.

Apremilast may help treat hair loss in alopecia areata.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

In this randomized, placebo-controlled study, the tested cosmetic ingredient containing Trifolium pratense flower extract and a biomimetic peptide increased anagen hair and improved the anagen/telogen ratio over four months in individuals with recessing hair.

In this study, methotrexate therapy with or without corticosteroids showed similar efficacy and safety in treating patients with lichen planopilaris, with no significant differences in the primary outcome or adverse effects between the two groups.

This study found that mycophenolate mofetil can enhance skin pigmentation in vitiligo models by activating the WNT signaling pathway and increasing melanin-related gene expression.

This article presents a planned trial comparing radiotherapy and imiquimod for lentigo maligna treatment, noting a lack of direct evidence supporting current therapies, and aims to inform future treatment guidelines.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This article discusses the efficacy and safety of mycophenolate mofetil and hydroxychloroquine for treating lichen planopilaris and reports no new clinical results.

In this study, researchers found that exosome-like nanoparticles isolated from Polygoni Multiflori Radix can promote hair growth in mice by modulating androgen signaling and gene expression, outperforming Minoxidil in testosterone-induced conditions.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study found that ulcerative colitis is associated with diverse molecular changes and chronic inflammation, with some biomarker levels partially recovering during remission.

This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.

This study found that retinoic acid and a retinol complex formulation showed different permeation and compound localization in a skin equivalent model, with unique lipid changes observed with only the retinol formulation.

This paper contains author contact information and disclosures without reporting new research findings or results.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.